Title
EGFR-directed therapies in squamous cell carcinoma of the head and neck
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
bookPart
Publication
London :Future Medicine, [*]
Subject
Human medicine
Source (book)
EGFR inhibitors in cancer treatment / Ciardiello, Fortunato [edit.]
ISBN - Hoofdstuk
978-1-78084-026-0
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
The EGF receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). EGFR-directed therapies include monoclonal antibodies and tyrosine kinase inhibitors. The addition of the monoclonal antibody cetuximab to irradiation improves the outcome in locoregionally advanced SCCHN. The addition of an EGFR-directed monoclonal antibody, particularly cetuximab, to a platinum-based chemotherapy improves the outcome in recurrent/metastatic SCCHN. EGFR-directed monoclonal antibodies have activity in platinum-refractory SCCHN, although the benefit might be less than expected. The activity of EGFR-directed tyrosine kinase inhibitors in SCCHN so far has been disappointing.
Handle